Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC

Inclusion Criteria: * Histologically confirmed stage IIIB/IV NSCLC. * Investigator confirmed progression according RECIST 1.1 during EGFR TKI treatment within 28 days of the randomization * Activating mutation (G719A/C/S; Exon 19 insertion/deletion; L858R; L861Q) in the EGFR gene or have had at least partial response with EGFR TKI lasting ≥ 6 months * Performance status: WHO 0-2 * Measurable disease according to RECIST 1.1 * Patients must be able to comply with study treatments * Women with child-bearing potential and men with reproductive potential must be willing to practice acceptable methods of birth control during the study * Neutrophils ≥ 1'000/μl, Platelets ≥ 100'000/μl, Alanine amino transferase ≤ 2.5 × Upper limit of normal (ULN) (\< 5 × ULN if liver metastases), Alkaline phosphatase ≤ 2.5 × ULN (\< 5 × ULN if liver metastases), Serum bilirubin ≤ 1.5 × ULN, Serum Creatinine ≤ 1.5 × ULN. * Patient must be able to comply with the protocol Exclusion Criteria: * RECIST 1.1 defined disease progression for more than 28 days while on previous EGFR TKI treatment. * Patient has been treated with any investigational agent for any indication within 4 weeks of study treatment. * Patient has history of hypersensitivity or intolerance to erlotinib or gefitinib. * Patient has history of hypersensitivity or intolerance to chemotherapeutic agents used in the study. * Patient with symptomatic central nervous system metastases * Patient has known active hepatitis B or C, or HIV infection * Pregnant or breastfeeding. * Patient with uncontrolled undercurrent illness or circumstances that could limit compliance with the study